drugset / Trial / NCT03006003

Osteoporosis Treatment in Post-menopausal Women

NCT03006003

Phase 4 Unknown 500 enrolled Taichung Veterans General Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Timeline

Start
2017-01-01
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 70 mg
Subject Raloxifene Other / unclassified Oral
Comparator Cholecalciferol Other / unclassified 70 ug

Indications